Preparing for the Unitary Patent

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Preparing for the Unitary Patent

Sponsored by

inspicos-400px recrop.jpg
christian-lue-8yw6tsb8tnc-unsplash.jpg

Jakob Pade Frederiksen of Inspicos P/S discusses the Unitary Patent and Unified Patent Court regime expected to enter into force by early 2023

The Unitary Patent (UP) and Unified Patent Court (UPC) regime is expected to enter into force in late 2022 or early 2023. Under the future system, patentees may request unitary effect for their patents in the 17 EU States currently participating to the system. Patents with unitary effect will not have to undergo country-by-country validation. 

The exact date of entry into force of the new system will be triggered by Germany’s depositing of its instrument of ratification of the Unified Patent Court Agreement. 

In preparation for the coming into existence of the new system, the EPO has implemented transitional measures applicable to European patent applications having reached the final stage of the grant proceedings. 

The measures will be available for European patent applications, in respect of which the EPO has issued its communication under Rule 71(3) EPC informing the applicant of the intention to grant a patent. 

The first transitional measure provides the possibility for applicants to file a request for unitary effect before the entry into force of the new system. Once the UP system has started, the EPO will register unitary effect. Requests for unitary effect cannot, however, be validly filed before Germany deposits its instrument of ratification, or before the communication under Rule 71(3) EPC has been issued.

The second transitional measure enables applicants to request a delay in the EPO’s issuing of the decision to grant a European patent until immediately after the entry into force of the  UP system. Patentees may thus benefit from unitary protection and hence avoid country-by-country validation in the 17 participating countries. However, only requests filed after the date of Germany’s depositing of its instrument of ratification will be allowed. 

In respect of cases, where time limits for replying to ‘office actions’, i.e., communications under Article 94(3) EPC, or time limits under Rule 71(3) EPC, are already running, applicants who wish to benefit from unitary protection may consider not lodging early replies with the EPO. Rather, applicants may wish to benefit from the full reply periods available in order to increase their chances of being able to benefit from the transitional measures.

 

 

Jakob Pade Frederiksen

Partner, Inspicos P/S

E: jpf@inspicos.com

 

more from across site and SHARED ros bottom lb

More from across our site

Niri Shan, the newly appointed head of IP for UK, Ireland and the Middle East, explains why the firm’s international setup has brought UPC success, and addresses German partner departures
Vlad Stanese joins our ‘Five minutes with’ series to discuss potentially precedent-setting trademark and copyright cases and his love for aviation
Heath Hoglund, president of Via LA, discusses how it sets royalty rates and its plans to build on growth in China
Stobbs stands accused of interfering with the administration of justice after Brandsmiths’ client was subjected to an interim injunction for unjustified threats
The firm, known for its prosecution expertise, discusses its plans following the appointment of a UK-based patent litigation head and two new partners
Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Rebecca Schwarz at Haynes Boone shares how her team secured victory for biopharma client RedHill in a licensing dispute involving a developmental cancer drug
News of a breakaway firm launching in Germany and a spike in vaccine-related patent applications were also among the top talking points
A flurry of hiring activity among UK firms suggests they are confident of mounting a serious challenge at the UPC
Gift this article